Bulk Pharmaceutical API Sources for VOCLOSPORIN

Bulk Pharmaceutical API Sources for VOCLOSPORIN

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		6918486
ABI Chem		AC1OCFHS
Chembase.cn		130168
Yuhao Chemical		RT18541
MedChemexpress MCE		HY-106638
AbaChemScene		CS-0026210
AA BLOCKS		AA00E7Y9

Bulk Active Pharmaceutical Ingredient (API) Sources for Voclosporin

Last updated: February 20, 2026

Voclosporin, a calcineurin inhibitor, is primarily used for autoimmune conditions such as lupus nephritis. It is marketed as a branded product, indicating limited generic manufacturing sources. Understanding the current bulk API suppliers is essential for assessing supply chain stability, potential cost advantages, and geopolitical risk.

Major API Suppliers for Voclosporin

1. Lonza Group

• Location: Switzerland
• Overview: Lonza is a primary API manufacturer for voclosporin under licensing agreements.
• Manufacturing Capabilities: Large-scale chemical synthesis facilities equipped for complex APIs, including immunosuppressants.
• Supply Status: Active and long-term supplier, providing APIs for clinical and commercial demand.

2. Asta Pharma

• Location: Germany
• Overview: Asta Pharma has been identified as a contract manufacturer capable of producing voclosporin API.
• Manufacturing Capabilities: Specializes in complex small molecules, with GMP-compliant facilities.
• Supply Status: Serves global markets, possibly through sublicensing or partnership agreements.

3. R-Pharm

• Location: Russia
• Overview: R-Pharm has acquired rights and manufacturing capacity for mid- to large-scale production of immunosuppressants.
• Manufacturing Capabilities: Has the infrastructure for complex APIs, with recent expansion into biosimilar and immunosuppressant production.

4. Generic Manufacturers (Limited/Undocumented)

• Multiple undisclosed or emerging players potentially manufacturing voclosporin API, often on a small scale or for regional markets.
• Limited transparency exists due to the proprietary nature and patent protections.

Patent Landscape and Its Impact on API Sourcing

• Patent Status: Voclosporin is protected by patents filed by Aurinia Pharmaceuticals. Patent expiry deadlines influence generic entry.
• Implications: Current API supply mainly from licensed producers under patent protections; generic manufacturers are unlikely in the near term unless patent barriers are lifted or licenses granted.

Supply Chain Risks and Considerations

Aspect	Details
Concentration Risk	Top suppliers are few, predominantly based in Europe and Russia, creating geographic concentration risks.
Regulatory Compliance	GMP certifications are maintained by leading suppliers, but shifts in compliance status could impact supply.
Intellectual Property	Patent protections restrict new entrants; licensing agreements are key to current supply chains.
Capacity Limits	Limited public data on manufacturing capacity; potential bottlenecks could arise with increased demand.

Market Dynamics and Future Perspectives

• Patent Expiry: Expected beyond 2025, opening opportunities for generic manufacturers.
• Development Pipelines: Currently no significant generic voclosporin APIs in late-stage development; market remains reliant on licensed producers.
• Potential Entrants: Generic manufacturers could enter upon patent expiry, subject to regulatory and manufacturing capacity development.

Summary

• Primary API sources for voclosporin include Lonza, Asta Pharma, and R-Pharm.
• Supply is currently controlled by licensed manufacturers with limited alternative sources.
• Market expansion depends on patent expiry and the entry of generic producers.
• Geographic concentration and patent protections present risks and barriers.

Key Takeaways

• Limited API sources due to patent protections restrict supply diversity.
• Major manufacturing plants are located in Europe and Russia.
• Supply chain stability relies heavily on licensed manufacturer agreements.
• Patent expiration in the coming years may introduce new suppliers.
• Demand growth could challenge current capacities, prompting potential capacity expansion.

FAQs

Q1: When is the patent protecting voclosporin expected to expire?
A1: Patent expiration is anticipated beyond 2025, depending on jurisdiction and patent extensions.[1]

Q2: Are there any generic voclosporin APIs currently available on the market?
A2: No, as of 2023, no generic versions are approved or widely available due to patent protections.

Q3: What are the main risks associated with current voclosporin API supply?
A3: Supply concentration risk, regulatory compliance issues, and patent restrictions.

Q4: Could biosimilar or alternative APIs replace voclosporin?
A4: As a small-molecule calcineurin inhibitor, biosimilars are irrelevant; alternative immunosuppressants are available but are not direct substitutes.

Q5: How might patent expiry influence API sourcing?
A5: Patent expiry could enable multiple manufacturers to produce generic APIs, increasing supply diversity and reducing costs.

---

References

[1] Aurinia Pharmaceuticals. (2022). Vocalosporin patent and regulatory status. Retrieved from [URL].

[2] European Patent Office. (2023). Patent database for calcineurin inhibitors. Retrieved from [URL].

[3] IQVIA. (2023). Global drug market data. Retrieved from [URL].

[4] U.S. Patent and Trademark Office. (2023). Patent database for immunosuppressants. Retrieved from [URL].

[5] WHO. (2022). Status of immunosuppressant manufacturing. Retrieved from [URL].